TNF and uveitis: The current study comprehensively included three types of biologics for the first time, i.e., TNF-α inhibitors, IL-17 inhibitors, and JAK inhibitors, involving 9 drugs (adalimumab, etanercept, golimumab, infliximab, secukinumab, bimekizumab, ixekizumab, tofacitinib, and upadacitinib) to analyze the impact of these drugs on the risk of new and recurrent uveitis in AS patients.